Nakao Hiroshi
Department of Infectious Diseases Research, National Children's Medical Research Center, National Children's Hospital.
Nihon Rinsho. 2002 Mar;60(3):545-50.
Shiga toxin producing Escherichia coli(STEC) has been recognized as an emerging food-borne pathogen that causes bloody diarrhea, hemorrhagic colitis and hemolytic uremic syndrome(HUS), especially in developed countries. As the specific therapy for STEC infection has not been developed, currently available medical therapy is inadequate to prevent life-threatening complications. Here are described the possibilities and problems of using and developing therapies such as antibiotics, Synsorb-Pk and humanized anti-Stx monoclonal antibody therapy. In conclusion, the prevention of primary infection is thought to be the best way to prevent the life-threatening complications caused by STEC, and second way is identification as early as possible.
产志贺毒素大肠杆菌(STEC)已被公认为一种新出现的食源性病原体,可导致血性腹泻、出血性结肠炎和溶血尿毒综合征(HUS),尤其是在发达国家。由于尚未开发出针对STEC感染的特异性疗法,目前可用的药物治疗不足以预防危及生命的并发症。本文描述了使用和开发抗生素、Synsorb-Pk和人源化抗Stx单克隆抗体疗法等治疗方法的可能性和问题。总之,预防原发性感染被认为是预防STEC所致危及生命并发症的最佳方法,其次是尽早识别。